Literature DB >> 3231951

On sample sizes to estimate the protective efficacy of a vaccine.

R T O'Neill1.   

Abstract

To estimate vaccine protective efficacy, defined as VE = 1 - ARV/ARU where ARV is the disease attack rate in the vaccinated group and ARU is the disease attack rate in the controls, investigators have used both cohort and case-control designs. For each design, we present a method for calculation of the sample size required to provide an approximate confidence interval for VE of predetermined width and probability of coverage. The required sample size is a function of the desired width of the confidence interval, the probability of coverage, the assumed VE, and, for cohort designs, the assumed disease attack rate in the controls, and for case-control designs, the assumed vaccine exposure prevalence for the controls.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3231951     DOI: 10.1002/sim.4780071208

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  7 in total

1.  Acaricidal efficacy against cattle ticks and acute oral toxicity of Lippia javanica (Burm F.) Spreng.

Authors:  James Madzimure; Emmanuel T Nyahangare; Humphrey Hamudikuwanda; Thokozani Hove; Philip C Stevenson; Steve R Belmain; Brighton M Mvumi
Journal:  Trop Anim Health Prod       Date:  2010-10-27       Impact factor: 1.559

2.  Attack rates of human papillomavirus type 16 and cervical neoplasia in primiparous women and field trial designs for HPV16 vaccination.

Authors:  M Kibur; V af Geijerstamm; E Pukkala; P Koskela; T Luostarinen; J Paavonen; J Schiller; Z Wang; J Dillner; M Lehtinen
Journal:  Sex Transm Infect       Date:  2000-02       Impact factor: 3.519

3.  BNT162b2 against COVID-19 in Brazil using a test-negative design: Study protocol and statistical analysis plan.

Authors:  Regis Goulart Rosa; Julia Spinardi; Kristen E Allen; Josélia Manfio; Cintia Laura Pereira de Araujo; Mírian Cohen; Caroline Cabral Robinson; Daniel Sganzerla; Diogo Ferreira; Emanuel Maltempi de Souza; Jaqueline Carvalho de Oliveira; Daniela Fiori Gradia; Ana Paula Carneiro Brandalize; Gabriela Almeida Kucharski; Fernando Pedrotti; Cristina de Oliveira Rodrigues; Moe H Kyaw; Graciela Del Carmen Morales Castillo; Amit Srivastava; John M McLaughlin; Maicon Falavigna
Journal:  PLoS One       Date:  2022-10-20       Impact factor: 3.752

4.  Efficacy of Strychnos spinosa (Lam.) and Solanum incanum L. aqueous fruit extracts against cattle ticks.

Authors:  James Madzimure; Emmanuel T Nyahangare; Humphrey Hamudikuwanda; Thokozani Hove; Steve R Belmain; Philip C Stevenson; Brighton M Mvumi
Journal:  Trop Anim Health Prod       Date:  2013-02-28       Impact factor: 1.559

5.  Using simulation to aid trial design: Ring-vaccination trials.

Authors:  Matt David Thomas Hitchings; Rebecca Freeman Grais; Marc Lipsitch
Journal:  PLoS Negl Trop Dis       Date:  2017-03-22

6.  COVID-19 vaccine effectiveness studies in Nigeria: Quo vadis?

Authors:  Oluwatosin Wuraola Akande; Ehimario Uche Igumbor; Kelly Osezele Elimian; Cornelius Ehizokhai Ohonsi; Lilian Nwozor; Okanke Oden; Emmanuel Nsa Ekpenyong; Nnaemeka Ndodo; Ifeanyi F Ike; Magdalene Egede; William Nwachukwu; Amedu M Onoja; Jenson Gawain Fofah; Reuben Ishiaku Azi; Chinwe L Ochu; Ifedayo M Adetifa
Journal:  J Glob Health       Date:  2022-08-03       Impact factor: 7.664

7.  Modelling the Economic Impact of lnfluenza Vaccine Programs with the Cell-Based Quadrivalent Influenza Vaccine and Adjuvanted Trivalent Influenza Vaccine in Canada.

Authors:  Van Hung Nguyen; Bertrand Roy
Journal:  Vaccines (Basel)       Date:  2022-08-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.